$XGN News

Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Exagen (XGN) Q1 2026 Earnings Transcript

Exagen Inc. Q1 2026 Earnings Call Summary

Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...

BTIG Maintains Buy on Exagen, Lowers Price Target to $8

Exagen Inc. 2026 Q1 - Results - Earnings Call Presentation

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses

Exagen Inc. (NASDAQ:XGN) Soars on Q1 2026 Earnings Beat as Record Revenue and Narrowed Loss Fuel Pre-Market Rally

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est

Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M Estimate

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?

How Analyst Resets Are Reshaping The Exagen (XGN) Investment Story

Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10